Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Anixa Biosciences
AddedFeb 19, 2024
UpdatedJun 18, 2026
Anixa Biosciences

Anixa Biosciences

Public

Anixa, a biotech firm, harnesses the immune system to combat cancer, develops cancer vaccines, and offers early tumor detection technology.

HQ
San Jose, CA, US
Founded
1982
Overview
Compare
Fundraising
Employees
Website

Anixa Biosciences, founded with a mission to harness the body's immune system to combat cancer, focuses on developing innovative therapies and vaccines for oncology. The company's core products include a cancer vaccine targeting α-Lactalbumin to prevent triple-negative breast cancer (TNBC) and a novel CAR-T based immunotherapy known as chimeric endocrine receptor T-cell (CER-T) technology. Anixa also offers Cchek™, a liquid biopsy technology for early tumor detection, addressing critical unmet needs in cancer treatment and prevention.

Notable figures affiliated with Anixa include its leadership team and key investors who have supported the company's pioneering work in biotechnology. Anixa has achieved significant milestones, such as advancing its CAR-T and cancer vaccine programs through various stages of development. The company's impact is marked by its potential to revolutionize cancer treatment and prevention, offering hope to patients through cutting-edge immunotherapy and early detection solutions.

Anixa Biosciences - Quick Facts

When was Anixa Biosciences founded?

Anixa Biosciences was founded in 1982.

Where is Anixa Biosciences' headquarters located?

Anixa Biosciences' headquarters is located in San Jose, CA, US.

How much has Anixa Biosciences raised to-date?

As of Dec 6, 2023, Anixa Biosciences has raised a total of $34.3M (USD).

How many employees does Anixa Biosciences have?

Anixa Biosciences has 4 employees as of Feb 6, 2024.

Anixa Biosciences - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Therapies
Tags
  • Biotech
Unique IDs
  • ein: 112622630
  • secCik: 0000715446
  • ticker: ANIX
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 51 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 333300Commercial and Service Industry Machinery Manufacturing
  • 333310Commercial and Service Industry Machinery Manufacturing
  • 334100Computer and Peripheral Equipment Manufacturing
  • 334400Semiconductor and Other Electronic Component Manufacturing
  • 334418Printed Circuit Assembly (Electronic Assembly) Manufacturing
  • 334600Manufacturing and Reproducing Magnetic and Optical Media
  • 530000Real Estate and Rental and Leasing
  • 533000Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
  • 533100Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
  • 533110Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
  • 621000Ambulatory Health Care Services
  • 621500Medical and Diagnostic Laboratories
  • 621510Medical and Diagnostic Laboratories
  • 621511Medical Laboratories
  • 621512Diagnostic Imaging Centers
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 333000Machinery Manufacturing
  • 334000Computer and Electronic Product Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 334110Computer and Peripheral Equipment Manufacturing
  • 334410Semiconductor and Other Electronic Component Manufacturing
  • 334610Manufacturing and Reproducing Magnetic and Optical Media
  • 325412Pharmaceutical Preparation Manufacturing
  • 334118Computer Terminal and Other Computer Peripheral Equipment Manufacturing
SIC
  • 3577Computer Peripheral Equipment, NEC
  • 6794Patent Owners And Lessors
  • 8070Medical And Dental Laboratories
  • 8071Medical Laboratories
  • 3500Industrial And Commercial Machinery And Computer Equipment
  • 4000Railroad Transportation
  • 5000Wholesale Trade-durable Goods
  • 6000Depository Institutions
  • 6700Holding And Other Investment Offices
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 3570Computer And Office Equipment
  • 6790Miscellaneous Investing
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 2610Manufacture of electronic components and boards
  • 2620Manufacture of computers and peripheral equipment
  • 2680Manufacture of magnetic and optical media
  • 7740Leasing of intellectual property and similar products, except copyrighted works
  • 8690Other human health activities